-

Shareholder Alert: Robbins LLP Announces that Aurora Cannabis, Inc. (ACB) is Being Sued for Misleading Shareholders

SAN DIEGO & EDMONTON, Alberta--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Aurora Cannabis, Inc. (NYSE: ACB) has filed a class action complaint against the company's officers for alleged violations of the Securities Exchange Act of 1934 between February 13, 2020 and September 4, 2020. Based in Edmonton, Canada, Aurora produces and distributes medical cannabis products worldwide.

If you suffered a loss due to Aurora Cannabis, Inc.'s misconduct, click here.

Aurora Cannabis, Inc. (ACB) Accused of Failing to Disclose Sizable Impairment Charges

According to the complaint, during the relevant period, Aurora Cannabis, Inc. failed to disclose that it had significantly overpaid for recently acquired assets while the value of others depreciated. When Canada passed the Cannabis Act in 2018 and reshaped the marijuana industry, Aurora completed a series of acquisitions intended to strengthen its position in the marketplace, including the purchase of MedReleaf, a medical cannabis producer, for 3.2 billion Canadian dollars. Aurora encountered issues such as regulatory delays, overproduction, and black market competition. On February 6, 2020, Aurora issued a press release detailing its business transformation plan, aimed at better aligning the company with the "current realities of the cannabis market." However, the plan was inadequate in addressing the company's situation. The plan's shortfall was even further evident after Aurora's September 8, 2020 press release, which revealed that the company expected to record $1.8 billion in goodwill charges in 2020's fourth quarter, including up to $90 million in fixed asset impairment charges, and $140 million to carry the value of certain inventory. On this news, Aurora stock price fell 11.63% to close at $7.52 per share on September 8, 2020.

If you purchased Aurora Cannabis, Inc. (ACB) securities between February 13, 2020 and September 4, 2020, you have until December 1, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Aurora Cannabis, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of The Simply Good Foods Company (SMPL) Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is investigating whether The Simply Good Foods Company misled investors regarding the successful integration of OWYN....

BE Stockholders Have Rights – If You Lost Money Investing in Bloom Energy Corporation Contact Robbins LLP for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Bloom Energy Corporation (NYSE: BE) securities between February 27, 2025 and July 8, 2026 (the "Class Period"). Bloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation in the United States and internationally. Scandium is a rare earth metal used as a dopant to...

Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company that focuses on developing smal...
Back to Newsroom